Abstract
Aims: We aimed to investigate the level and predictive value of soluble nectin-4 in early onset preeclampsia (EOPE).
Methods: Forty-three patients with EOPE and 41 healthy normotensive pregnant women participated in this prospective case-control study. The groups were matched for gestational age and gravidity. Serum nectin-4 levels were compared between groups. The ROC curve was drawn to show the predictive value of nectin-4 for EOPE. Patients were followed up until the end of labor, and perinatal outcomes were recorded.
Results: The demographic characteristics of the two groups were similar. Serum nectin-4 level was significantly increased in EOPE cases compared to controls (226.46±119.6 ng/ml vs. 156.54±44.8 ng/ml, p=0.001). The ROC showed that at > 160.938, the sensitivity and specificity were 67.44% and 82.93%, respectively [AUC:0.822, (CI:0.724 - 0.897), and (p< 0.001)]. Significant inverse correlations were found between nectin-4 levels and poor obstetric outcomes.
Conclusion: Maternal serum nectin-4 levels were significantly higher in patients with EOPE compared with controls. Increased nectin-4 levels may contribute to the development of EOPE through possible oxidative, immunological, and inflammatory mechanisms adversely affecting trophoblastic cells.
Keywords
References
- Gestational Hypertension and Preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135(6):e237.
- Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209(6):544.e1-544.e12.
- Harmon QE, Huang L, Umbach DM, et al. Risk of fetal death with preeclampsia. Obstet Gynecol. 2015;125(3):628-635.
- Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094-1112.
- Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? Placenta. 2014;35 Suppl:S20-25.
- Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011;66(8):497-506.
- Obut M, Oğlak SC. Expression of CD44 and IL-10 in normotensive and preeclamptic placental tissue. Ginekol Pol. 2020;91(6):334-341.
- Ito M, Nishizawa H, Tsutsumi M, et al. Potential role for nectin-4 in the pathogenesis of pre-eclampsia: a molecular genetic study. BMC Med Genet. 2018;19:166.
- Wang Y, Walsh SW. TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol. 1996;32(2):157-169.
- Reymond N, Fabre S, Lecocq E, Adelaïde J, Dubreuil P, Lopez M. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem. 2001;276(46):43205-43215.
- Adu-Gyamfi EA, Czika A, Gorleku PN, et al. The involvement of cell adhesion molecules, tight junctions, and gap junctions in human placentation. Reprod Sci Thousand Oaks Calif. 2021;28(2):305-320.
- Fabre-Lafay S, Monville F, Garrido-Urbani S, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer. 2007;7:73.
- Karabulut M, Gunaldi M, Alis H, et al. Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2016;18(2):160-171.
- Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest. 1993;91(3):950-960.
- Oudejans CBM, van Dijk M, Oosterkamp M, Lachmeijer A, Blankenstein MA. Genetics of preeclampsia: paradigm shifts. Hum Genet. 2007;120(5):607-612.
- Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 2001;344(12):867-872.
- Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2002;2(9):656-663.
- Meggyes M, Nagy DU, Szigeti B, et al. Investigation of mucosal-associated invariant T (MAIT) cells expressing immune checkpoint receptors (TIGIT and CD226) in early-onset preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2020;252:373-381.
- Hackmon R, Koifman A, Hyodo H, Glickman H, Sheiner E, Geraghty DE. Reduced third-trimester levels of soluble human leukocyte antigen G protein in severe preeclampsia. Am J Obstet Gynecol. 2007;197(3):255.e1-5.
- Steinborn A, Varkonyi T, Scharf A, Bahlmann F, Klee A, Sohn C. Early detection of decreased soluble HLA-G levels in the maternal circulation predicts the occurrence of preeclampsia and intrauterine growth retardation during further course of pregnancy. Am J Reprod Immunol NYN 1989. 2007;57(4):277-286.
- Goswami D, Tannetta DS, Magee LA, et al. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta. 2006;27(1):56-61.
- M-Rabet M, Cabaud O, Josselin E, et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(4):769-776.
- Reches A, Ophir Y, Stein N, et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. J Immunother Cancer. 2020;8(1):e000266.
- Fu W, Ma Z, Lei C, Ding M, Hu S. TIGIT-Fc Promote Immune Tolerance at the Feto-maternal Interface [Internet]. bioRxiv. 2019:819243. doi: https://doi.org/10.1101/819243
- Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48-57.
- Rzymski T, Petry A, Kračun D, et al. The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene. 2012;31(31):3621-3634.
- Gomaa MF, Naguib AH, Swedan KH, Abdellatif SS. Serum tumor necrosis factor-α level and uterine artery Doppler indices at 11-13 weeks’ gestation for preeclampsia screening in low-risk pregnancies: a prospective observational study. J Reprod Immunol. 2015;109:31-35.
- Ma R, Gu Y, Groome LJ, Wang Y. ADAM17 regulates TNFα production by placental trophoblasts. Placenta. 2011;32(12):975-980.
- Siddharth S, Nayak A, Das S, et al. The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-β4. Int J Biochem Cell Biol. 2018;102:151-160.
- Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn. 2009;29(5):464-470.
- Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol. 2011;31(1):33-46.
- Hirashima C, Ohkuchi A, Matsubara S, et al. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res. 2008;31(8):1541-1548.
- Hu T, Wang G, Zhu Z, Huang Y, Gu H, Ni X. Increased ADAM10 expression in preeclamptic placentas is associated with decreased expression of hydrogen sulfide production enzymes. Placenta. 2015;36(8):947-950.
- Buchanan PC, Boylan KLM, Walcheck B, et al. Ectodomain shedding of the cell adhesion molecule nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J Biol Chem. 2017;292(15):6339-6351.
- Yoshizawa H, Nishizawa H, Ito M, et al. Increased levels of nectin-4 as a serological marker for pre-eclampsia. Fujita Med J. 2023;9(3):200-205.
Abstract
References
- Gestational Hypertension and Preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135(6):e237.
- Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209(6):544.e1-544.e12.
- Harmon QE, Huang L, Umbach DM, et al. Risk of fetal death with preeclampsia. Obstet Gynecol. 2015;125(3):628-635.
- Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094-1112.
- Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? Placenta. 2014;35 Suppl:S20-25.
- Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011;66(8):497-506.
- Obut M, Oğlak SC. Expression of CD44 and IL-10 in normotensive and preeclamptic placental tissue. Ginekol Pol. 2020;91(6):334-341.
- Ito M, Nishizawa H, Tsutsumi M, et al. Potential role for nectin-4 in the pathogenesis of pre-eclampsia: a molecular genetic study. BMC Med Genet. 2018;19:166.
- Wang Y, Walsh SW. TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol. 1996;32(2):157-169.
- Reymond N, Fabre S, Lecocq E, Adelaïde J, Dubreuil P, Lopez M. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem. 2001;276(46):43205-43215.
- Adu-Gyamfi EA, Czika A, Gorleku PN, et al. The involvement of cell adhesion molecules, tight junctions, and gap junctions in human placentation. Reprod Sci Thousand Oaks Calif. 2021;28(2):305-320.
- Fabre-Lafay S, Monville F, Garrido-Urbani S, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer. 2007;7:73.
- Karabulut M, Gunaldi M, Alis H, et al. Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2016;18(2):160-171.
- Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest. 1993;91(3):950-960.
- Oudejans CBM, van Dijk M, Oosterkamp M, Lachmeijer A, Blankenstein MA. Genetics of preeclampsia: paradigm shifts. Hum Genet. 2007;120(5):607-612.
- Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 2001;344(12):867-872.
- Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2002;2(9):656-663.
- Meggyes M, Nagy DU, Szigeti B, et al. Investigation of mucosal-associated invariant T (MAIT) cells expressing immune checkpoint receptors (TIGIT and CD226) in early-onset preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2020;252:373-381.
- Hackmon R, Koifman A, Hyodo H, Glickman H, Sheiner E, Geraghty DE. Reduced third-trimester levels of soluble human leukocyte antigen G protein in severe preeclampsia. Am J Obstet Gynecol. 2007;197(3):255.e1-5.
- Steinborn A, Varkonyi T, Scharf A, Bahlmann F, Klee A, Sohn C. Early detection of decreased soluble HLA-G levels in the maternal circulation predicts the occurrence of preeclampsia and intrauterine growth retardation during further course of pregnancy. Am J Reprod Immunol NYN 1989. 2007;57(4):277-286.
- Goswami D, Tannetta DS, Magee LA, et al. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta. 2006;27(1):56-61.
- M-Rabet M, Cabaud O, Josselin E, et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(4):769-776.
- Reches A, Ophir Y, Stein N, et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. J Immunother Cancer. 2020;8(1):e000266.
- Fu W, Ma Z, Lei C, Ding M, Hu S. TIGIT-Fc Promote Immune Tolerance at the Feto-maternal Interface [Internet]. bioRxiv. 2019:819243. doi: https://doi.org/10.1101/819243
- Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48-57.
- Rzymski T, Petry A, Kračun D, et al. The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene. 2012;31(31):3621-3634.
- Gomaa MF, Naguib AH, Swedan KH, Abdellatif SS. Serum tumor necrosis factor-α level and uterine artery Doppler indices at 11-13 weeks’ gestation for preeclampsia screening in low-risk pregnancies: a prospective observational study. J Reprod Immunol. 2015;109:31-35.
- Ma R, Gu Y, Groome LJ, Wang Y. ADAM17 regulates TNFα production by placental trophoblasts. Placenta. 2011;32(12):975-980.
- Siddharth S, Nayak A, Das S, et al. The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-β4. Int J Biochem Cell Biol. 2018;102:151-160.
- Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn. 2009;29(5):464-470.
- Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol. 2011;31(1):33-46.
- Hirashima C, Ohkuchi A, Matsubara S, et al. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res. 2008;31(8):1541-1548.
- Hu T, Wang G, Zhu Z, Huang Y, Gu H, Ni X. Increased ADAM10 expression in preeclamptic placentas is associated with decreased expression of hydrogen sulfide production enzymes. Placenta. 2015;36(8):947-950.
- Buchanan PC, Boylan KLM, Walcheck B, et al. Ectodomain shedding of the cell adhesion molecule nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J Biol Chem. 2017;292(15):6339-6351.
- Yoshizawa H, Nishizawa H, Ito M, et al. Increased levels of nectin-4 as a serological marker for pre-eclampsia. Fujita Med J. 2023;9(3):200-205.
Details
| Primary Language | English |
|---|---|
| Subjects | Obstetrics and Gynaecology |
| Journal Section | Original Article |
| Authors | |
| Early Pub Date | October 28, 2023 |
| Publication Date | October 29, 2023 |
| Published in Issue | Year 2023 Volume: 6 Issue: 6 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
|
|
|
| |
|
|
|
|
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
|
|
|
|
|
|
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.